Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

Michael Anstead, Sonya L. Heltshe, Umer Khan, Joseph T. Barbieri, Markus Langkamp, Gerd Döring, Shimoni Dharia, Ronald L. Gibson, Miriam M. Treggiari, James Lymp, Margaret Rosenfeld, Bonnie Ramsey

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood. Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication. Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60. week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation. Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.

Original languageEnglish (US)
Pages (from-to)147-153
Number of pages7
JournalJournal of Cystic Fibrosis
Issue number2
StatePublished - Mar 2013
Externally publishedYes


  • EPIC
  • Infection
  • Pseudomonas
  • Serology
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial'. Together they form a unique fingerprint.

Cite this